The Human Immunodeficiency Virus Type 1 Ribosomal Frameshifting Site Is an Invariant Sequence Determinant and an Important Target for Antiviral Therapy

Journal of Virology

Volumn 78, Issue 4, 2004, Pages 2082-2087

  Biswas, Preetha ^a   Jiang, Xi ^a   Pacchia, Annmarie L ^a   Dougherty, Joseph P ^a   Peltz, Stuart W ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b PTC THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAG PROTEIN; POL PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; FRAMESHIFT MUTATION; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIFE CYCLE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RIBOSOMAL FRAMESHIFTING; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; VIRUS INFECTIVITY; VIRUS SLIPPERY SITE;

ANTI-HIV AGENTS; BASE SEQUENCE; CELL LINE; FRAMESHIFTING, RIBOSOMAL; FUSION PROTEINS, GAG-POL; GENE PRODUCTS, GAG; HELA CELLS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; VIRUS REPLICATION;

EID: 0842304470     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.4.2082-2087.2004     Document Type: Article

References (30)

1. Aiken, C. 1997. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71:5871-5877.
2. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1992. Current protocols in molecular biology, vol. 2. John Wiley & Sons, Inc., New York, N.Y.
3. Brierley, I. 1995. Ribosomal frameshifting viral RNAs. J. Gen. Virol. 76: 1885-1892.
4. Brierley, I., A. J. Jenner, and S. C. Inglis. 1992. Mutational analysis of the "slippery-sequence" component of a coronavirus ribosomal frameshifting signal. J. Mol. Biol. 227:463-479.
5. Chamorro, M., N. Parkin, and H. E. Varmus. 1992. An RNA pseudoknot and an optimal heptameric shift site are required for highly efficient ribosomal frameshifting on a retroviral messenger RNA. Proc. Natl. Acad. Sci. USA 89:713-717.
6. Chen, C., and H. Okayama. 1998. Calcium phosphate-mediated gene transfer: a highly efficient system for stably transforming cells with plasmid DNA. BioTechniques 6:632-638.
7. Cohen, J. 2001. AIDS research. Debate begins over new vaccine trials. Science 293:1973.
8. Dinman, J. D., T. Icho, and R. B. Wickner. 1991. A-1 ribosomal frameshift in a double-stranded RNA virus of yeast forms a gag-pol fusion protein. Proc. Natl. Acad. Sci. USA 88:174-178.
9. Dinman, J. D., S. Richter, E. P. Plant, R. C. Taylor, A. B. Hammell, and T. M. Rana. 2002. The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure. Proc. Natl. Acad. Sci. USA 99:5331-5336.
10. 1 double-stranded RNA virus propagation. J. Virol. 66:3669-3676.
11. Dulude, D., M. Baril, and L. Brakier-Gingras. 2002. Characterization of the frameshift stimulatory signal controlling a programmed - 1 ribosomal frameshift in the human immunodeficiency virus type 1. Nucleic Acids Res. 30: 5094-5102.
12. Farabaugh, P. J. 1996. Programmed translational frameshifting. Annu. Rev. Genet. 30:507-528.
13. Gesteland, R. F., and J. F. Atkins. 1996. Recoding: dynamic reprogramming of translation. Annu. Rev. Biochem. 65:741-768.
14. Grentzmann, G., J. A. Ingram, P. J. Kelly, R. F. Gesteland, and J. F. Atkins. 1998. A dual-luciferase reporter system for studying recoding signals. RNA 4:479-486.
15. Hill, M. K., M. Shehu-Xhilaga, S. M. Crowe, and J. Mak. 2002. Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability. J. Virol. 76:11245-11253.
16. Jacks, T., H. D. Madhani, F. R. Masiarz, and H. E. Varmus. 1988. Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell 55:447-458.
17. Jacks, T., M. D. Power, F. R. Masiarz, P. A. Luciw, P. J. Barr, and H. E. Varmus. 1988. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331:280-283.
18. Jacks, T., and H. E. Varmus. 1985. Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting. Science 230:1237-1242.
19. Kang, H. 1998. Direct structural evidence for formation of a stem-loop structure involved in ribosomal frameshifting in human immunodeficiency virus type 1. Biochim. Biophys. Acta 1397:73-78.
20. Kaplan, A. H., J. A. Zack, M. Knigge, D. A. Paul, D. J. Kempf, D. W. Norbeck, and R. Swanstrom. 1993. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67:4050-4055.
21. Kaul, M., H. Yu, Y. Ron, and J. P. Dougherty. 1998. Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences. Virology 249: 167-174.
22. Kuiken, C., B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, and B. E. Korber. 2001. HIV-1 sequence compendium 2001. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N.Mex.
23. Luukkonen, B. G., W. Tan, and S. Schwartz. 1995. Efficiency of reinitiation of translation on human immunodeficiency virus type 1 mRNAs is determined by the length of the upstream open reading frame and by intercistronic distance. J. Virol. 69:4086-4094.
24. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
25. Pacchia, A. L., M. E. Adelson, M. Kaul, Y. Ron, and J. P. Dougherty. 2001. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 282:77-86.
26. Parkin, N. T., M. Chamorro, and H. E. Varmus. 1992. Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo. J. Virol. 66:5147-5151.
27. Paulus, C., S. Hellebrand, U. Tessmer, H. Wolf, H. G. Krausslich, and R. Wagner. 1999. Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein. J. Biol. Chem. 274: 21539-21543.
28. Pettit, S. C., G. J. Henderson, C. A. Schiffer, and R. Swanstrom. 2002. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 76:10226-10233.
29. Richman, D. D. 2002. HIV chemotherapy. Nature 410:995-1001.
30. Vaishnav, Y. N., and F. Wong-Staal. 1991. The biochemistry of AIDS. Annu. Rev. Biochem. 60:577-630.